HERG Screening Market Growth Patterns And Forecast Outlook Through 2030

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The HERG Screening Market Be By 2030 Compared To Its 2026 Market Size?

The herg screening market has seen a rapid increase in size over recent years. It is anticipated to expand from $1.84 billion in 2025 to $2.06 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.0%. The historical growth trajectory is largely due to factors such as an increase in cardiac-related drug withdrawals, enhanced investment in preclinical safety studies, the expansion of pharmaceutical R&D, the implementation of in-vitro ion channel assays, and heightened awareness concerning drug-induced arrhythmias.

The herg screening market is anticipated to experience significant expansion over the coming years, with its size projected to reach $3.21 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.7%. This growth during the forecast period is attributable to progress in AI-driven predictive toxicology, the incorporation of organ-on-chip technologies, the increasing development of biologics and personalized medicine, a rise in outsourcing to CDMOs, and the expansion of preclinical research in developing markets. Key trends identified for this period encompass sophisticated cardiotoxicity modeling, automated high-throughput screening, the embedding of predictive analytics within preclinical safety assessments, an increase in contract research services, and the use of miniaturized microfluidic assays.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14392&type=smp

Which Factors Are Influencing The Growth Of The HERG Screening Market?

An increasing prevalence of individuals suffering from heart ailments is anticipated to boost the expansion of the HERG screening market. Cardiovascular disorders, also known as heart diseases, encompass various conditions impacting the heart and blood vessels, potentially impairing heart function and leading to severe health issues. Factors contributing to these conditions include unhealthy lifestyles, an aging demographic, genetic predispositions, diabetes, and metabolic syndrome. HERG screening plays a crucial role in identifying suitable drug candidates, thereby preventing serious cardiac events such as life-threatening arrhythmias, notably torsade de pointes (TdP), and ultimately enhancing patient welfare. For example, the Australian Institute of Health and Welfare, an Australia-based government agency, reported in October 2025 that approximately 57,100 adults aged 25 and above experienced acute coronary events in 2023, averaging around 156 occurrences daily. Consequently, the growing number of patients with heart disorders is propelling the HERG screening market forward. The increasing proportion of older individuals in society is anticipated to propel the expansion of the HERG screening market. An aging population signifies a higher percentage of elderly people within a community, largely attributed to longer life expectancies and declining birth rates. Healthcare advancements, which have extended human lifespan, are a key factor in this demographic shift. HERG screening serves the aging demographic by ensuring the safety of novel pharmaceuticals for elderly patients, specifically by detecting compounds that might induce adverse cardiac effects. For instance, in January 2024, the Population Reference Bureau, a US-based non-profit organization, stated that the number of Americans aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050, representing a 47% rise. During this timeframe, this cohort’s share of the total U.S. population is expected to grow from 17% to 23%. Consequently, the growing aging population is a significant catalyst for the HERG screening market.

How Are Segments Identified Within The HERG Screening Market Segment Framework?

The herg screening market covered in this report is segmented –

1) By Type: Gene KCNH2, Mutant KCNH2

2) By Ion Channel: Voltage-Gated, Ligand Gated

3) By Applications: Antiarrhythmic, Antipsychotic, Antibiotics, Other Applications

Subsegments:

1) By Gene KCNH2: Wild-Type KCNH2, Recombinant KCNH2

2) By Mutant KCNH2: Mutations: Missense Mutations, Nonsense Mutations, Frameshift Mutations

Which Trends Are Guiding The Direction Of The HERG Screening Market?

Leading companies in the HERG screening market are focusing on innovative advanced solutions, such as GLP-certified HERG screening services, to enhance cardiac safety assessments during drug development processes. This service entails the good laboratory practice-certified screening of the human ether-à-go-go related gene (hERG) utilizing the conventional whole-cell patch-clamp technique. It ensures that screening adheres to regulatory guidelines like ICH S7A and ICH S7B, which are vital for safety pharmacology studies in drug development. For instance, in August 2023, Metrion Biosciences Ltd., a UK-based pharmaceutical company, launched its good laboratory practice (GLP)-certified hERG screening service. This service aims to improve Metrion’s support for small-molecule therapeutic development and augment the company’s existing cardiac safety service portfolio. Moreover, this service employs the conventional whole-cell patch-clamp technique to evaluate potential cardiac liabilities before entering Phase 1 clinical trials in humans, offers regulatory guidance for safety pharmacology studies in drug development, and provides clients with high-quality biology services for ion channel targets.

Who Are The Companies Competing Within The HERG Screening Market?

Major companies operating in the herg screening market are Eurofins-Cerep SA, Aviva Biosciences Inc., AstraZeneca Public Limited Company, Merck KGaA, Charles River Laboratories Inc., Abcam Public Limited Company, Molecular Devices LLC, Caliper Life Sciences Inc., ChanTest Corporation, Creative Bioarray Inc., Cellular Dynamics International Inc., Nanion Technologies, Essen Bioscience, ACEA Biosciences Inc., Metrion Biosciences Inc., Aurora Biomed Inc., Aureus Sciences, RedShift BioAnalytics, Sophion Bioscience Inc., Fluxion Biosciences Inc.

Get The Full HERG Screening Market Report:

https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report

Where Is The HERG Screening Market Most Concentrated Geographically?

North America was the largest region in the HERG screening market in 2025. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the herg screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized HERG Screening Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report

Browse Through More Reports Similar to the Global HERG Screening Market 2026, By The Business Research Company

Herg Screening Market Report 2026

https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report

Cellular Health Screening Market Report 2026

https://www.thebusinessresearchcompany.com/report/cellular-health-screening-global-market-report

Carrier Screening Market Report 2026

https://www.thebusinessresearchcompany.com/report/carrier-screening-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795